Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Julien Dilly

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4006-5285; OpenAlex author ID A5032228878. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
1
Labs led
0
Collaborators
48
Papers, trials and grants by year

2023: 1 paper, 1 grant · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117314↗
  2. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  3. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  4. Integrative genomic identification of therapeutic targets for pancreatic cancer. Co-author DOI 10.1016/j.celrep.2025.116191↗
  5. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  6. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  7. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  8. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗

Grants 1

  1. Fellowship: Julien Dilly (response and resistance to RAS-pathway inhibition) AWARD pancan:2023-julien-dilly-ms-fellowship-julien-dilly-response-and-res

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 5 shared papers, 2023–2026 · strength 0.92
  2. Brian Matthew Wolpin · 3 shared papers, 2023–2026 · strength 0.52
  3. William L. Hwang · 2 shared papers, 2025–2026 · strength 0.41
  4. Dennis H. Gong · 2 shared papers, 2025–2026 · strength 0.41
  5. Carina Shiau · 2 shared papers, 2025–2026 · strength 0.41
  6. Jimmy A. Guo · 2 shared papers, 2025–2026 · strength 0.41
  7. Seema Chugh · 2 shared papers, 2025–2026 · strength 0.41
  8. Jonathan Andrew Nowak · 2 shared papers, 2023–2026 · strength 0.34
  9. Harshabad Singh · 2 shared papers, 2023–2025 · strength 0.32
  10. Nicholas J Caldwell · 1 shared paper, 2026 · strength 0.22
  11. Mingjuan Lisa Zhang · 1 shared paper, 2026 · strength 0.22
  12. Mari A. Mino-Kenudson · 1 shared paper, 2026 · strength 0.22
  13. Tyler Jacks · 1 shared paper, 2026 · strength 0.22
  14. Szu-Aun Lim · 1 shared paper, 2026 · strength 0.21
  15. A. Cole Edwards · 1 shared paper, 2026 · strength 0.21
  16. Syed Arif Ahmad · 1 shared paper, 2026 · strength 0.21
  17. Kirsten L. Bryant · 1 shared paper, 2026 · strength 0.21
  18. Adrienne D. Cox · 1 shared paper, 2026 · strength 0.21
  19. Sarah E. Ackermann · 1 shared paper, 2026 · strength 0.21
  20. Clint A. Stalnecker · 1 shared paper, 2026 · strength 0.21
  21. Andrew M. Waters · 1 shared paper, 2026 · strength 0.21
  22. Channing J. Der · 1 shared paper, 2026 · strength 0.21
  23. G. Aaron Hobbs · 1 shared paper, 2026 · strength 0.21
  24. Craig M. Goodwin · 1 shared paper, 2026 · strength 0.21
  25. Joseph Douglas Mancias · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.